These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26001026)

  • 21. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.
    Amico KR; Wallace M; Bekker LG; Roux S; Atujuna M; Sebastian E; Dye BJ; Elharrar V; Grant RM
    AIDS Behav; 2017 May; 21(5):1361-1375. PubMed ID: 27317411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.
    Koss CA; Bacchetti P; Hillier SL; Livant E; Horng H; Mgodi N; Mirembe BG; Gomez Feliciano K; Horn S; Liu AY; Glidden DV; Grant RM; Benet LZ; Louie A; van der Straten A; Chirenje ZM; Marrazzo JM; Gandhi M
    AIDS Res Hum Retroviruses; 2017 Aug; 33(8):778-783. PubMed ID: 28253024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment.
    R Amico K; McMahan V; Goicochea P; Vargas L; Marcus JL; Grant RM; Liu A
    AIDS Behav; 2012 Jul; 16(5):1243-59. PubMed ID: 22460228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010.
    Kebaabetswe PM; Stirratt MJ; McLellan-Lemal E; Henderson FL; Gray SC; Rose CE; Williams T; Paxton LA
    AIDS Behav; 2015 May; 19(5):758-69. PubMed ID: 25186785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial.
    Drain P; Ngure K; Mugo N; Spinelli M; Chatterjee P; Bacchetti P; Glidden D; Baeten J; Gandhi M
    JMIR Res Protoc; 2020 Apr; 9(4):e15029. PubMed ID: 32238341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attitudes Towards PrEP and Anticipated Condom Use Among Concordant HIV-Negative and HIV-Discordant Male Couples.
    Hoff CC; Chakravarty D; Bircher AE; Campbell CK; Grisham K; Neilands TB; Wilson PA; Dworkin S
    AIDS Patient Care STDS; 2015 Jul; 29(7):408-17. PubMed ID: 26057304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
    Haberer JE
    Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
    Mugo PM; Sanders EJ; Mutua G; van der Elst E; Anzala O; Barin B; Bangsberg DR; Priddy FH; Haberer JE
    AIDS Behav; 2015 May; 19(5):794-801. PubMed ID: 25432877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings.
    Marcus JL; Volk JE; Pinder J; Liu AY; Bacon O; Hare CB; Cohen SE
    Curr HIV/AIDS Rep; 2016 Apr; 13(2):116-24. PubMed ID: 26898645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.
    Fonsart J; Saragosti S; Taouk M; Peytavin G; Bushman L; Charreau I; Hance A; Goldwirt L; Morel S; Mammano F; Loze B; Capitant C; Clavel F; Mahjoub N; Meyer L; Anderson PL; Delaugerre C; Molina JM
    J Antimicrob Chemother; 2017 Feb; 72(2):478-485. PubMed ID: 28073964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value.
    Abaasa A; Hendrix C; Gandhi M; Anderson P; Kamali A; Kibengo F; Sanders EJ; Mutua G; Bumpus NN; Priddy F; Haberer JE
    AIDS Behav; 2018 Apr; 22(4):1165-1173. PubMed ID: 29090394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.
    Spinelli MA; Lowery B; Shuford JA; Spindler J; Kearney MF; McFarlane JR; McDonald C; Okochi H; Phung N; Kuncze K; Jee K; Johannessen D; Anderson PL; Smith DK; Defechereux P; Grant RM; Gandhi M
    Clin Infect Dis; 2021 Jun; 72(11):2025-2028. PubMed ID: 32686825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention.
    Drain PK; Bardon AR; Simoni JM; Cressey TR; Anderson P; Sevenler D; Olanrewaju AO; Gandhi M; Celum C
    Curr HIV/AIDS Rep; 2020 Oct; 17(5):487-498. PubMed ID: 32627120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.
    Stalter RM; Baeten JM; Donnell D; Spinelli MA; Glidden DV; Rodrigues WC; Wang G; Vincent M; Mugo N; Mujugira A; Marzinke M; Hendrix C; Gandhi M;
    Clin Infect Dis; 2021 Feb; 72(3):486-489. PubMed ID: 33527128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach.
    Seidman DL; Weber S; Cohan D
    J Int AIDS Soc; 2017 Mar; 20(Suppl 1):21295. PubMed ID: 28361503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial.
    Musinguzi N; Muwonge T; Thomas K; Baeten JM; Bangsberg DR; Haberer JE
    AIDS Behav; 2016 Nov; 20(11):2639-2643. PubMed ID: 26781865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acceptability of HIV Pre-Exposure Prophylaxis (PrEP) and Implementation Challenges Among Men Who Have Sex with Men in India: A Qualitative Investigation.
    Chakrapani V; Newman PA; Shunmugam M; Mengle S; Varghese J; Nelson R; Bharat S
    AIDS Patient Care STDS; 2015 Oct; 29(10):569-77. PubMed ID: 26348459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation Program.
    Pintye J; Kinuthia J; Abuna F; Mugwanya K; Lagat H; Dettinger JC; Odinga D; Sila J; Anderson PL; John-Stewart G; Baeten JM
    Clin Infect Dis; 2020 Dec; 71(9):e509-e512. PubMed ID: 32109293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.
    Lu Y; Goti V; Chaturvedula A; Haberer JE; Fossler MJ; Sale ME; Bangsberg D; Baeten JM; Celum CL; Hendrix CW
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5379-86. PubMed ID: 27353269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges to PrEP use and perceptions of urine tenofovir adherence monitoring reported by individuals on PrEP.
    Hunt T; Lalley-Chareczko L; Daughtridge G; Swyryn M; Koenig H
    AIDS Care; 2019 Oct; 31(10):1203-1206. PubMed ID: 30821473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.